Trial Profile
A retrospective study aseessing the efficacy of Elvitegravir/emtricitabine/tenofovir-disoproxil-fumarate/cobicistat fixed dose combination in virologically suppressed HIV-1 infected adults with or without the archived NRTI resistance mutation M184V/I
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Dec 2016
Price :
$35
*
At a glance
- Drugs Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 30 Dec 2016 New trial record